Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

830

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Cancer (Adenocarcinoma)

Interventions

DRUG: Abiraterone
DRUG: Enzalutamide
DRUG: Apalutamide
DRUG: Darolutamide (BAY 1841788)
DRUG: Docetaxel
DRUG: ADT

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]